Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.

导出 LinkOut

翻译打印收藏纠错

作者： Nina,Worel ^[1] ; Gerhard,Fritsch ^[2] ; Hermine,Agis ^[3] ; Alexandra,Böhm ^[4] ; Georg,Engelich ^[5] ; Gerda C,Leitner ^[1] ; Klaus,Geissler ^[6] ; Karoline,Gleixner ^[7] ; Peter,Kalhs ^[8] ; Veronika,Buxhofer-Ausch ^[4] ; Felix,Keil ^[9] ; Gerhard,Kopetzky ^[10] ; Viktor,Mayr ^[11] ; Werner,Rabitsch ^[8] ; Regina,Reisner ^[9] ; Konrad,Rosskopf ^[12] ; Reinhard,Ruckser ^[13] ; Claudia,Zoghlami ^[6] ; Niklas,Zojer ^[14] ; Hildegard T,Greinix ^[15]

作者单位： Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria. ^[1] Children?s Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung, Vienna, Austria. ^[2] Medical Department I, Division of Oncology, Medical University of Vienna, Vienna, Austria. ^[3] First Medical Department, Elisabethinen Hospital, Linz, Austria. ^[4] First Medical Department, Hospital Wiener Neustadt, Austria. ^[5] Department of Internal Medicine V, Hospital Hietzing, Vienna, Austria. ^[6] Medical Department I, Division of Haematology, Medical University of Vienna, Vienna, Austria. ^[7] Medical Department I, Bone Marrow Transplantation Unit, Medical University Vienna, Vienna, Austria. ^[8] Third Medical Department, Hanusch Hospital, Vienna, Austria. ^[9] Department of Medicine I, General Hospital, St Poelten, Austria. ^[10] Medical Department II, Hospital Krems, Austria. ^[11] Department of Blood Group Serology, Medical University Graz, Graz, Austria. ^[12] Medical Department II, Division of Oncology, Donauhospital Vienna, Vienna, Austria. ^[13] Department of Internal Medicine I, Wilhelminen Hospital, Vienna, Austria. ^[14] Division of Haematology, Medical University of Graz, Austria. ^[15]

关键词 binding inhibitor poor stem cell mobilization preemptive approach